SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-23-034686
Filing Date
2023-10-19
Accepted
2023-10-19 16:01:11
Documents
6
Period of Report
2023-12-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A def14a-2023a.htm DEF 14A 615095
2 GRAPHIC avalo-logoxblka.jpg GRAPHIC 48586
3 GRAPHIC capnetlossgrapha.jpg GRAPHIC 222093
4 GRAPHIC captsrgrapha.jpg GRAPHIC 204342
5 GRAPHIC proxycard_avalotherapeut001.jpg GRAPHIC 133147
6 GRAPHIC proxycard_avalotherapeut002.jpg GRAPHIC 116010
  Complete submission text file 0001628280-23-034686.txt   1613276
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37590 | Film No.: 231334753
SIC: 2834 Pharmaceutical Preparations